About Xarelto

Xarelto (rivaroxaban) is an anticoagulant (blood thinner) that prevents the formation of blood clots. It was approved by the U.S. Food and Drug Administration (FDA) in 2011 and is manufactured by Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. Xarelto is used to prevent or treat a type of blood clot called deep vein thrombosis (DVT), which can lead to blood clots in the lungs (pulmonary embolism). This medication is also used in people with atrial fibrillation (a heart rhythm disorder) to lower the risk of stroke caused by a blood clot.

The manufacturers are facing lawsuits stating that Xarelto is unsafe and defective. The plaintiffs claim that, unlike traditional anticoagulants (e.g. Warfarin, Coumadin) whose blood-thinning effects can be reversed using vitamin K, there is no antidote available for Xarelto. Because of this, the lawsuits claim, doctors have no effective means of stopping Xarelto users from bleeding in the event of an emergency. Plaintiffs in the lawsuits allege serious and fatal injuries, including cerebral hemorrhaging and gastrointestinal bleeds, from use of the drug.

Because Xarelto’s manufacturers, Janssen Pharmaceuticals and Bayer AG, might not have properly warned consumers about the potential risks associated with Xarelto. Users of the drug (or their loved ones) might be eligible to demand compensation by filing a Xarelto lawsuit. If you, or a loved one, developed internal bleeding or passed away while taking Xarelto you may be entitled to compensation. Please complete the form below and one of our attorneys will contact you - or call 1-800-LAW-FIRM now.

Cases, Settlements, & Verdicts

The first case against Bayer Corp. was filed in the in the Philadelphia County Court of Common Pleas by Kentucky resident Virginia Stuntebeck in February 2014. She suffered from gastrointestinal bleeding which landed her into the hospital in 2013. She claims that Bayer and Johnson and Johnson were negligent in introducing the drug to the market and also questioned the warning label on the drug.